ACCD:NSD-Accolade Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 17.59

Change

-1.65 (-8.58)%

Market Cap

USD 1.20B

Volume

2.45M

Avg Analyst Target

USD 38.00 (+116.03%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Accolade Inc (ACCD) Stock Analysis:
Based on the Accolade Inc stock forecasts from 11 analysts, the average analyst target price for Accolade Inc is USD 38.00 over the next 12 months. Accolade Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Accolade Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Accolade Inc’s stock price was USD 17.59. Accolade Inc’s stock price has changed by -0.49% over the past week, -8.72% over the past month and -67.17% over the last year.

About

Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a ...Read More

Company Website : https://www.accolade.com

Address : 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Employees : 2,350

Fiscal Year End : February

Currency: USD

Country : USA

Technical Indicators

52 Week High : 56.72

Short Ratio : 5.57

52 Week Low : 16.59

Shorted Shares : 4,546,246

200 Day Moving Average : 41.12

Shorted Shares Previous Month : 4,421,737

50 Day Moving Average : 25.72

Shares Held By Insiders : 3.66%

Short Percentage : 7.10%

Shares Held by Institutions : 73.09%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

-0.34 (-0.37%)

 USD26.80B 53.94 13.44
TXG 10x Genomics Inc

-4.03 (-4.26%)

 USD10.57B N/A N/A
GDRX GoodRx Holdings Inc

-0.28 (-1.16%)

 USD9.66B 927.27 238.21
OMCL Omnicell Inc

-3.57 (-2.36%)

 USD6.51B 85.49 44.39
INOV Inovalon Holdings Inc

N/A

 USD6.37B 122.57 33.93
CHNG Change Healthcare Inc

-0.59 (-2.95%)

 USD6.22B N/A 13.81
RCM R1 RCM Inc

-0.55 (-2.46%)

 USD5.99B 72.63 31.09
PINC Premier Inc

-0.66 (-1.72%)

 USD4.70B 18.11 11.24
HQY HealthEquity Inc

+0.30 (+0.58%)

 USD4.29B 789.30 27.55
PGNY Progyny Inc

-0.27 (-0.71%)

 USD3.45B 42.07 117.41

ETFs Containing ACCD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.27% 8% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.27% 8% F 9% F
Trailing 12 Months  
Capital Gain -67.17% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.17% 23% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.01% 13% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.01% 13% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 17.26% 84% B 79% C+
Risk Adjusted Return -34.82% 16% F 10% F
Market Capitalization 1.20B 57% F 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 96% A
Price/Book Ratio 1.59 84% B 65% D
Price / Cash Flow Ratio -47.69 77% C+ 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -15.85% 38% F 36% F
Return on Invested Capital -21.29% 28% F 28% F
Return on Assets -9.08% 31% F 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.57 34% F 18% F
Short Percent 7.10% 29% F 24% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector